O varian germ cell tumors are rare tumors that occur during adolescence and young adulthood. Yolk sac tumor (YST) is a common histologic subtype, occurring either as an exclusive entity or admixed with other malignant subtypes. Whereas among pediatric practitioners, YST is considered a chemosensitive tumor, it is often cited as an adverse prognostic factor in adult women with ovarian germ cell tumor (GCT). 1, 2 The Malignant Germ Cell International Consortium (MaGIC) has amalgamated data from past clinical trials in pediatric and medical oncology that allows for the interrogation of questions such as this across the boundary of age. 3Y5 The objective of the present study was thus to explore whether age is an independent risk factor for outcome in O-YST, considering other covariates such as stage, preoperative alpha-fetoprotein (AFP) level, chemotherapy regimen, and histology.
METHODS AND POPULATION Patient Population
After the signing of a memorandum of understanding, which specified the variables to be included, patient data from 8 GCT clinical trials conducted by the Children's Oncology Group (COG), the Children's Cancer and Leukemia Group (United Kingdom), the Gynecologic Oncology Group (GOG; United States of America), and the French Society of Pediatric Oncology SFCE were analyzed. Patients' characteristics included in the data set were age at enrollment, date of initial surgery, stage, preoperative AFP level, treatment regimen, histology, and outcome. Table 1 provides further details on each clinical trial,  including the chemotherapeutic regimens. 6Y13 MaGIC has been reviewed and exempted by the institutional review board at the Dana-Farber Cancer Institute.
Staging Considerations
Different staging systems were used in the various clinical trials (Table 2) . 14Y16 International Federation of Gynecology and Obstetrics (FIGO) stage IA/B, COG stage I, and postsurgical tumor nodes metastases (TNM) stage I were excluded from the study; FIGO stage IV, COG stage IV, and clinical or postoperative TNM stage IV were referred to as ''stage IV.'' The remaining patients were referred to as having ''stage II/III'' and analyzed as a single entity because it was not possible to reconcile how these stages relate to one another in the absence of the primary surgical data.
Histology
If a YST component was identified on the clinical trial record, the tumors were defined as ''definitive YST'' and split into 2 groups: ''pure YST'' if the tumor contained exclusively YST or YST plus teratoma and ''mixed YST'' if the YST component was associated with at least one of the following malignant GCT histologies: choriocarcinoma, embryonal carcinoma, or dysgerminoma. In some cases, details on histology were not provided in clinical trial record and patients were classified as having a ''putative O-YST'' if the pretherapeutic level of AFP was Q1000 ng/mL. This designation was based on expert consensus of the members of the MaGIC.
Statistical Analysis
The primary outcomes were event-free survival (EFS) and overall survival (OS). Event-free survival was defined as the time interval from the date of diagnosis to relapse or progression of malignant germ cell tumor, second malignancy, death regardless of cause, or date last seen (whichever occurred first). Overall survival was defined as the time interval from the date of diagnosis to death regardless of cause or date last seen (whichever occurred first). Survival curves were calculated using the Kaplan-Meier analysis. 17 Differences in outcome for covariates (preoperative AFP, stage, histology, and regimen) were compared using the log-rank test.
18 P G 0.05 was regarded as a statistically significant difference.
The association between risks of EFS event and death and age in whole years at the date of enrollment on the relevant clinical trial (''age'') was assessed in 3 ways. In the 18 In the second characterization, age was divided into 3 categories: children aged 0 to 10 years, adolescents aged 11 to 17 years, and adults 18 years or older. Frazier et al 3 demonstrated patients with nonsemminomatous GCTs (NSGCT) who were younger than 11 years were at significantly reduced risk for EFS event when compared with patients 11 years or older. The cutoff at 18 years was chosen as a classical definition of adulthood. The third characterization was a best cutoff analysis: All possible cut points of age were examined and maximum value of the log-rank W 2 was obtained. To calculate the P value for the log-rank W 2 correcting for the method by which the cut point was selected, 1000 data sets where age was not associated with risk for EFS-event were created by permuting the values of age among individuals in the original dataset. The maximum log rank chi square was calculated for each of these replications and the correct P-value was calculated as the proportion of datasets created by permutation where the maximum log rank chi square was greater than or equal to the maximum value of the log-rank W 2 .
RESULTS

Patients' and Disease Characteristics
The data set includes 252 patients. Stage was missing for one patient who was subsequently excluded from further description and analyses. Characteristics of the 251 patients aged 0 to 38 years (median, 13 years; standard deviation, 5.8 years) are detailed in Table 3 . Seventy-eight were children (0Y10 years), 139 were adolescents (11Y17 years) and 34 were adults (Q18 years). Twenty-six patients (10%) were stage IV, similarly distributed in the 3 age groups. Tumors were pure, mixed, and putative YST in 129, 56, and 66 cases, respectively. Median level of AFP was 11,977 ng/mL (range, 3Y4,233,000 ng/mL) in the entire cohort, and 9184 ng/ml in the subgroup of patients with putative YST (range, 1062Y4,233,000 ng/mL). Pretherapeutic levels were missing in 29 adults, 12 adolescents, and 3 children. The proportion of children (18%) and adolescents (19%) treated with carboplatin was the same, whereas all the adults were treated with cisplatin.
Prognostic Factors
The median follow-up for the entire cohort was 5.8 years (range, 0.02Y23 years); 24 experienced an event and 13 (Fig. 1) . The 5-y EFS in the 0Y10, 11Y17, and 18 and older groups were 95% (95% CI, 86%Y98%), 89% (95% CI, 82%Y93%), and 93% (95% CI, 74%Y98%), respectively. The risk for EFS event was not significantly different between the 3 age groups (P = 0.29; Fig. 2 ). Five-year OS values were 96% (95% CI, 87%Y99%), 95% (95% CI, 90%Y98%), and 100% in the 3 age groups (P = 0.86). Age as a continuous variable was not related to risk of EFS event or death (hazard ratio, 1.03; 95% CI, 0.8Y1.2). The best cutoff analysis identified an age of 27 years as the most informative. However, this cut point was not significant after adjustment of the P value as described above (P =0.39). None of the covariates (ie, stage, preoperative AFP level, histology, and chemotherapy regimen) had significant prognostic impact on EFS or OS. Univariate analyses are shown in Table 4 . In a sensitivity analysis, the risk for EFS event and death of the putative O-YST did not differ significantly from the patients with definitive YST (P = 0.24 and P = 0.53, respectively).
DISCUSSION
The current study confirms that age itself has no impact on excellent outcomes of women with O-YST, whether modeling age as both a categorical and continuous variable, or analyzing through best cutoff. Putative O-YST patients' risk for EFS event and death did not differ significantly from the patients that we could confirm had a histological diagnosis of YST. Similarly, other covariates such as stage, preoperative AFP level, chemotherapy regimen, and histology had no apparent effect on outcome.
In the literature, O-YST have an overall good prognosis, ranging from an OS of more than 95% for FIGO stage I tumors 8, 10, 19 to at least 65% for FIGO stages III and IV treated with platinum-based chemotherapy.
19Y21 Cure rates have dramatically improved since introduction of platinum agents, and the current low rates of events combined with the rarity of the disease have limited the identification of adverse prognostic factors in the modern area. To date, adverse prognostic factors in O-YST have been reported in small series (ranging from 22 to 211 patients). Of note, many of these series include a significant proportion of FIGO stage I tumors. Table 5 FIGURE 2. Event-free survival depending on the age groups. 20, 23, 25, 26 Nevertheless, a large series reporting on 211 patients with O-YST found that age older than 22 years was independently and significantly (P = 0.02) associated with poor OS. 21 Several series have reported a worse outcome in women with O-YST aged 40 or older 1, 22 and in postmenopausal O-YST. 27 Since our oldest patient was 38 years, it was impossible to substantiate this finding. Nevertheless, 92% of women had their diagnosis of NSGCT at age younger than age 40, according to Surveillance, Epidemiology, and End Results Program (data not shown, www. seer.cancer.gov). Therefore, we think that our data are generalizable to most of the women with NSGCT that contain a YST component. In a series comparing the outcome of patients with testicular GCTs, a lower EFS was observed in adolescents (13-19 years) compared to either children or adults, with 3-year EFS of 59.9%, 87.2%, and 80.0%, respectively (P = 0.011); nevertheless, survival was not statistically different among the 3 groups. 28 We have not found the ''gap'' in EFS in the current series, even if outcomes were slightly inferior in the 11 to 17 population, compared to younger and older groups.
High stage is commonly reported as adverse prognostic factor, but only when early stages (ie, FIGO I +/j II) were compared to higher stages (FIGO III and IV). 3 The discrepancy between these results and ours might be explained by differences in histology (all types of GCT in Frazier et al 3 versus YST in the current series). Moreover, the numbers of stage IV ovarian tumors in patients older than 11 were low in both series (9 in Frazier et al 3 versus 22 in the current series), precluding from drawing any definitive conclusions.
A limitation of our study was the extent of missing data for AFP (85%) in the adult patient group. High levels of serum AFP has been reported to be a prognostic factor in ovarian GCT. 29, 30 However, the cutoff values for AFP were defined differently in each study. In other series, including the MaGICrevised risk classification, 3 AFP levels were not found to affect on outcome. 19, 24, 25 In our study, the absence of AFP is unlikely to change our conclusions regarding the absence of impact of age, since it has itself no impact on outcome in the current studies.
The impact of histology subtype on outcome remains unclear. Within YST subtypes, hepatoid subtype 19 or an admixture of 3 or 4 YST subtypes 31 has been reported in univariate analysis to have a detrimental impact. In the current series, we were not able to comment on the prognostic impact of YST subtypes. When comparing pure YST to mixed YST, published series have failed to show a prognostic effect. 20,24Y26 However, the definition of mixed tumor varies from one series to another and thus precludes direct comparisons. In our analyses, we would have expected more mixed tumors in the adult group. Distribution of histologies was probably affected by the way the population has been selected: we may have included women with AFP 1000 ng/mL or greater who did not have a YST component. Likewise, we may not have included women with an O-YSTwho had an AFP less than 1000 ng/mL. Both scenarios would likely bias the results toward the null.
CONCLUSIONS
Ovarian yolk sac tumors have excellent outcomes, even in the context of metastatic spread. Despite a variety of methodologic approaches, a relationship between age and outcome was not demonstrable in women with O-YST who were younger than 40. This finding positions pediatric and gynecologic oncology specialties to collaborate on joint clinical trial development for germ cell tumors.
